PTE

PolarityTE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9995
+0.0001
+0.01%
After Hours: 0.9990 -0.0005 -0.05% 17:08 10/23 EDT
OPEN
1.020
PREV CLOSE
0.9994
HIGH
1.020
LOW
0.9799
VOLUME
155.02K
TURNOVER
--
52 WEEK HIGH
4.600
52 WEEK LOW
0.7800
MARKET CAP
38.90M
P/E (TTM)
-0.4205
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Why Co-Diagnostics Stock Soared 25% in September
MotleyFool.com · 10/08 09:28
What Are The Economic Impacts Of COVID-19?
As fears about the pandemic grow, global markets are seeing trillions of dollars disappear as the economic impact of coronavirus wreaks havoc on economies across the world.
Benzinga · 10/07 18:06
PolarityTE announces termination of shareholder rights plan
PolarityTE (PTE) terminates the shareholder rights plan after receiving stockholder input and evaluating that input in the context of Company objectives.The termination of the shareholder rights plan, often referred to
Seekingalpha · 09/29 12:27
PolarityTE Announces Termination of Shareholder Rights Plan
PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder input and evaluating that input in the context of Company objectives. The termination of the shareholder rights plan, often referred to as a
Business Wire · 09/29 12:00
PolarityTE secures research grant from NIH
PolarityTE (PTE) rises 5.5% in premarket, after being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health ((NIH)) for point-of-care devices to treat chronic wounds.”The Phase I
Seekingalpha · 09/21 12:17
PolarityTE Receives NIH Grant For Point-of-Care Device To Treat Chronic Wounds
PolarityTE, Inc. (NASDAQ:PTE) today announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health (NIH) for an application titled,
Benzinga · 09/21 12:15
PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds
PolarityTE, Inc. (Nasdaq: PTE) today announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health (NIH) for an application titled, "Fluid Management System for Point of Care Device for Novel Regenerative Treatment
Business Wire · 09/21 12:00
SkinTE Health EconomicsDFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure
PolarityTE, Inc. (Nasdaq: PTE) today announced cost per product data from the protocol-specified interim analysis in the Company’s ongoing randomized controlled trial (RCT) evaluating SkinTE for the treatment of diabetic foot ulcers (DFUs), which previously reported statistically significant wound closure
Business Wire · 09/16 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTE. Analyze the recent business situations of PolarityTE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTE stock price target is 3.333 with a high estimate of 4.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 109
Institutional Holdings: 9.51M
% Owned: 24.43%
Shares Outstanding: 38.92M
TypeInstitutionsShares
Increased
9
451.50K
New
31
-1.82M
Decreased
24
2.24M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Independent Director
Peter Cohen
President/Chief Operating Officer
Richard Hague
Chief Executive Officer/Director
David Seaburg
Chief Financial Officer
Jacob Patterson
Executive Vice President/General Counsel/Secretary
Cameron Hoyler
Director
Chris Nolet
Vice President
Sharon Whalen
Director
Jessica Shen
Director
Jay Hood
Independent Director
Minnie Baylor-Henry
Independent Director
Willie Bogan
Independent Director
Jeff Dyer
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
01/04/2016
Dividend USD 0.33550232
01/19/2016
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PTE
PolarityTE, Inc., formerly Majesco Entertainment Company, is the owner of patent applications and know-how related to regenerative medicine and tissue engineering, as well as software applications used in diagnosis and treatment related to regenerative medicine. The Company seeks to develop and obtain regulatory approval for technology that will utilize a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The Company's PolarityTE platform simplifies regeneration and allows cells to function naturally. The platform can be applied across all cells, tissues and composite structures. The Company focuses on various products, including SkinTE, OsteoTE, AngioTE, MyoTE, CartTE, AdiposeTE and NeuralTE. The Company, through SkinTE, is focused on supplying an autologous construct to regenerate a patient’s skin due to a variety of injuries and conditions.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Polarityte Inc stock information, including NASDAQ:PTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTE stock methods without spending real money on the virtual paper trading platform.